د. ريان فلمبان | علاج وظيفي

New research just dropped, and it changes how we think about “muscle memory.” I’m reading a study in American Journal of Physiology – Cell Physiology showing that human muscles keep an epigenetic memory of HIIT training. After 2 months of HIIT, then 3 months of no training, researchers still found persistent DNA changes in muscle cells. When people trained again, key genes linked to lactate transport and calcium signaling were already primed and more active. Your muscles don’t fully “forget” intense training. Even when fitness drops, the molecular blueprint from past workouts remains, making it easier for the body to adapt again. This study identified memory signatures in genes like SLC16A3, CAPN2, INPP5A, ADAM19, and MTHFD1L, which stayed hypomethylated even after detraining. Past HIIT literally leaves a biological imprint in your muscle. Missed training for a while? Your body may still remember more than you think.

Brazilian researchers at the Federal University of Rio de Janeiro (UFRJ) have achieved a major milestone in regenerative medicine: after more than 25 years of research, polylaminin a polymerized form of the natural protein laminin, has received approval from Anvisa for Phase 1 clinical trials in humans with acute, complete spinal cord injuries. Initial human trials (including phase 1 safety studies approved in early 2026) are yielding encouraging early outcomes: some individuals with severe spinal cord injuries have shown partial return of voluntary movement, improved motor control, and basic functions previously thought permanently lost. What medical science long considered irreversible is starting to shift toward possible recovery. The approach leverages a polymerized form of laminin (a natural protein) to promote axon regrowth, bridge injury sites, reduce inflammation, and support neural reconnection essentially kickstarting the body's own repair processes while safeguarding remaining nerve cells. For years, spinal cord injuries meant lifelong symptom management with little hope of restoring function. This therapy challenges that reality, potentially opening doors for millions affected by paralysis around the globe. Reports from the studies highlight notable gains in mobility, coordination, and muscle strength in early phases. Experts stress that these results while exciting and historic remain PRELIMINARY. Larger trials are essential to confirm long-term safety, efficacy, and scalability. Even so, this milestone from Brazil's dedicated teams represents a pivotal moment in neuroscience, edging the vision of meaningful recovery for spinal cord injury patients closer to reality than ever before.